rTMS on Mismatch Negativity of Schizophrenia

Schizophrenia Clinical Trial

Official title:

Using Repetitive Transcranial Magnetic Stimulation to Improve the Auditory Mismatch Negativity Deficits of Schizophrenia: a Randomized, Double-blinded, Sham-controlled Clinical Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04012684
• Other study ID #: 201807026RINB
• Status: Recruiting
• Phase: N/A
• Start date: September 5, 2019
• Est. completion date: February 28, 2021

Study information

• Verified date: August 2020
• Source: National Taiwan University Hospital
• Contact: Yi-Ting Lin
• Phone: +886-23123456
• Email: yit.lin[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Auditory mismatch negativity deficit is a robust neurophysiological biomarker of schizophrenia. Repetitive transcranial magnetic stimulation (rTMS) is a neuromodulation method and can be used to modulate excitability of specific brain cortical region. We hypothesize that MMN deficit of schizophrenia is related to inferior frontal gyrus (IFG) hypofunction, and this deficit can be improved by using rTMS to enhance IFG function.

It is a randomized, double-blinded, sham-controlled clinical trial. Forty-eight schizophrenia patients with MMN deficits (mean amplitude at FCz > -0.7 ㎶) will be recruited and then randomized at a 1:1 ratio to rTMS group and sham-stimulation group. Subjects in rTMS group will receive high frequency rTMS over IFG, while in the other group subjects will receive sham stimulation at IFG. Frameless stereotaxy navigation will be used to guide the rTMS coil to IFG. The primary outcome is the change of MMN mean amplitude at FCz after stimulation. We hypothesize that the change of MMN mean amplitude is significantly larger in rTMS group than in sham-stimulation group. Their cognitive function and clinical condition will be evaluated carefully before and after experiments.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 48
• Est. completion date: February 28, 2021
• Est. primary completion date: February 28, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years to 45 Years

Eligibility

Inclusion Criteria:

• diagnosis of schizophrenia according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision

• mean amplitude of MMN at FCz greater than -0.7 ?

• moderate or milder disease severity (scoring 4 or below according to clinical global rating scale)

Exclusion Criteria:

• unwillingness or inability to cooperate with the experiments

• with mental retardation, epilepsy, or other major brain pathology (e.g. cerebrovascular accidents or major head injury)

• with alcohol or other illicit substance abuse

• with major debilitating systemic diseases or difficulties in ambulation

• with hearing impairments as screened by audiometry over 500 Hz, 1000 Hz and 6000 Hz

• with pacemaker, intra-ocular metal foreign body, intracerebral vessel clip, artificial cardiac valve, electronic implant in the body, claustrophobia, or previous surgery involving the brain

• being pregnant or to be pregnant during the clinical trial. A pre-TMS evaluation scale will be applied to ensure the safety

Related Conditions & MeSH terms

• Mismatch Negativity
• Schizophrenia

Intervention

Device:
• Transcranial magnetic stimulation
For one-session rTMS, 50 trains of stimulation are given. Each train is consisted of 4-second 10 Hz, 100% resting motor threshold TMS pulses. The inter-train interval is 26 seconds.
• Sham
For one-session sham stimulation, 50 trains of stimulation are given. Each train is consisted of 4-second 10 Hz sham pulses. The inter-train interval is 26 seconds.

Locations

Country	Name	City	State
Taiwan	Department of Psychiatry, National Taiwan University Hospital	Taipei

Sponsors (1)

Lead Sponsor	Collaborator
National Taiwan University Hospital

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mismatch negativity (MMN)	Mismatch negativity is recorded by electroencephalography and elicited by auditory oddball paradigm in which tone duration deviants are used. MMN is the mean amplitude between 135 and 205 milliseconds after auditory stimuli recorded by electrode FCz.	1 day
Secondary	Continuous performance test (CPT)	The undegraded 1-9 task and the 25% degraded 1-9 task are used. Sensitivity indices indicating the ability to discriminate target from non-target trials are calculated (d' for undegraded CPT and md' for degraded CPT).	1 day
Secondary	Wisconsin Card Sorting Test (WCST)	Four indices of WCST are derived: perseverative errors, categories achieved, trials to complete first category, and conceptual level response.	1 day